Generic Drugs Take Center Stage

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-12-02-2002, Volume 26, Issue 12

Reform legislation about generic drugs remains at the forefront of debate as innovator companies poise to challenge FDA proposals regarding patent laws.

Related Content:

Quality SystemsRegulatory WatchGeneric DrugsDosage FormsPharmaceutical Technology-12-02-2002
FDA Reports on Status of Postmarketing Requirements and Postmarketing Commitments
Novartis’ Radioligand Therapy Gains FDA Nod for Pediatric Patients
Navigating an Uncertain Regulatory Environment for mRNA-based Products